Study name |
CoV‐Hep Study: randomized and paired clinical trial comparing regional anticoagulation modalities in continuous venous venous hemodialysis in patients with COVID‐19 |
Starting date |
29 June 2020 |
Contact information |
Paulo Lins, MD University of São Paulo General Hospital São Paulo, SP, Brazil, 05403‐010 +55.11.98279‐2696 | paulo.lins@hc.fm.usp.br
|
Methods |
Open‐label, 2‐armed, parallel RCT |
Participants |
90 participants, ≥ 18 years, female and male Inclusion criteria:
Exclusion criteria:
Hypersensitivity to any of the substances used in the study (citric acid dextrosol 2.2% and UFH)
Previous diagnosis of coagulopathy or thrombophilia
Contraindication to the use of UFH by the assistant team
Risk of citrate poisoning ‐ (lactate > 30 mg/dL, INR > 2.5, total bilirubin > 15mg/dL)
Pregnancy
|
Interventions |
Experimental:
Participants on continuous haemodialysis (blood flow 150 mL/min, dose of 30 mL/kg/h) receiving anticoagulation with sodium citrate at 4 mmol/L associated with UFH at 10 U/kg/h
Addition of UFH to CVVHD system already running under citrate regional anticoagulation
Comparator
|
Outcomes |
Primary
Secondary
-
Time‐free of clotting (time frame: day 3 of dialysis)
-
Number of dialysers used (time frame: day 3 of dialysis)
-
Pressure variation (time frame: day 3 of dialysis)
-
Urea sieving (time frame: day 3 of dialysis)
-
Downtime of dialysis (time frame: day 3 of dialysis)
|
Notes |
NCT04487990 | No data provided | |